EcoDrugPlus

V-Akt Murine Thymoma Viral Oncogene Homolog 2, Like

Ensembl ID : ENSTNIG00000008591
Gene Symbol: AKT2L
2 Cross references
161 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 3a

Ensembl ID : ENSTNIG00000002713
Gene Symbol: AKT3A
2 Cross references
200 Possible Orthologues:

V-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A

Ensembl ID : ENSTNIG00000002231
Gene Symbol: RELA
2 Cross references
198 Possible Orthologues:

V-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A

Ensembl ID : ENSTNIG00000003566
Gene Symbol: RELA
2 Cross references
198 Possible Orthologues:

Vascular Endothelial Growth Factor Ab

Ensembl ID : ENSTNIG00000009142
Gene Symbol: VEGFAB
2 Cross references
201 Possible Orthologues:

Vitamin D Receptor

Ensembl ID : ENSTNIG00000005559
Gene Symbol: VDR
3 Cross references
388 Possible Orthologues:

Vitamin K Epoxide Reductase Complex, Subunit 1

Ensembl ID : ENSTNIG00000015203
Gene Symbol: VKORC1
2 Cross references
189 Possible Orthologues:

Vitamin K Epoxide Reductase Complex, Subunit 1

Ensembl ID : ENSTNIG00000006213
Gene Symbol: VKORC1
2 Cross references
189 Possible Orthologues:

Xanthine Dehydrogenase

Ensembl ID : ENSTNIG00000006598
Gene Symbol: XDH
2 Cross references
208 Possible Orthologues:

Zgc:171772

Ensembl ID : ENSTNIG00000007910
Gene Symbol: ZGC:171772
3 Cross references
420 Possible Orthologues:

Ensembl ID : ENSTNIG00000016384
Gene Symbol: PARP1
2 Cross references
209 Possible Orthologues:

Ensembl ID : ENSTNIG00000000144
Gene Symbol: -
1 Cross references
165 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).